"It appears that this medicine will see the light of day at best at the end of the coming year and not in the beginning," Gintsburg told Russian broadcaster Rossiya 1.
Earlier in the month, Gintsburg said that the center would begin the drug's clinical trials next January and expected to be completed within 3-4 months.